Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Sezary syndrome is an aggressive leukemic variant of cutaneous T-cell lymphoma defined by a triad of widespread skin reddening (erythroderma), enlarged lymph nodes (lymphadenopathy), and circulating malignant T-lymphocytes known as Sezary cells in the peripheral blood. The malignant cells are clonally expanded mature helper T-cells that abnormally traffic among skin, lymph nodes, and bloodstream. Sezary syndrome is classified as a rare primary cutaneous lymphoma and predominantly affects adults in middle to later life. Precise prevalence estimates are not well established given its rarity. Care requires coordination across dermatology, hematology-oncology, and supportive specialties. This summary reflects clinical data available as of 2025.
Clinical Presentation
Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 2:57 PM UTC
Diseases are connected by shared genes, phenotypes, therapeutic targets, and MONDO disease hierarchy. The Rare badge reflects Kisho's rarity classification — scored from authoritative sources including OMIM, Orphanet, orphan drug designations, clinical trial activity, and published prevalence data.
→What are the benefits and potential side effects of POTELIGEO for managing Sezary syndrome?
→Are any of the 35 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?
FAQ
Frequently Asked Questions
Common questions about Sezary syndrome
Sezary syndrome is an aggressive form of cutaneous T-cell lymphoma. It is characterized by a triad of findings that include widespread red skin (erythroderma), swollen lymph nodes (lymphadenopathy), and the presence of abnormal lymphocytes in the blood, known as Sezary cells. This condition is rare and has a distinct clinical presentation from other types of lymphoma.
People with Sezary syndrome often show signs such as a red, inflamed skin and enlarged lymph nodes. Doctors also identify abnormal blood cells called Sezary cells, which help in recognizing this condition.
Information about causes is currently limited for this condition.
The clinical presentation spans the skin and integument, the lymphatic system, and the musculature, consistent with a multi-system malignancy.
Skin and integument: Erythroderma — diffuse reddening covering most of the body surface — is the hallmark finding and is accompanied by intense, often debilitating pruritus (itching). The skin becomes dry, thickened, and scaly, with fissuring and altered pigmentation. Lower-limb swelling may also occur.
Lymphatic and immune system: Enlarged lymph nodes are present in most individuals. Sezary cell circulation progressively compromises immune function, markedly increasing infection susceptibility. Infectious complications are a leading source of morbidity.
Musculature: Systemic inflammation contributes to generalized weakness and fatigue that substantially affect daily functioning and quality of life.
Explore clinical features
Genetic Landscape
Assembled from HGNC gene records, ClinGen gene-disease validity evidence, and ClinVar pathogenic variant data. Validity classifications reflect the strength of published evidence linking each gene to this disease.
Sezary syndrome arises from clonal proliferation of malignant mature T-lymphocytes and is an acquired malignancy rather than an inherited condition. No specific germline mutation consistently underlies its development. Chromosomal instability and disruption of T-cell signaling pathways are recognized molecular features. Environmental exposures, prior chronic inflammatory skin disease, and immune dysregulation have been proposed as contributing factors, but definitive causal relationships have not been established. Because Sezary syndrome is not inherited, family members are not at elevated genetic risk.
Diagnosis
Drawn from GeneReviews diagnostic guidelines, newborn screening panel status (RUSP), and ClinGen gene-disease validity classifications. Reflects current clinical evidence and consensus where available.
Diagnosis integrates clinical, laboratory, and histopathological findings. Established criteria require erythroderma, peripheral blood involvement with a defined threshold of circulating Sezary cells or an aberrant T-cell immunophenotype, and clonal T-cell receptor gene rearrangement. Skin biopsy with immunohistochemistry characterizes the dermal infiltrate, and flow cytometry quantifies and phenotypes the abnormal blood population. Lymph node biopsy is performed when lymphadenopathy is prominent.
Differential diagnosis is critical because several conditions mimic Sezary syndrome: erythrodermic mycosis fungoides, adult T-cell leukemia-lymphoma, and inflammatory erythrodermas from atopic dermatitis, psoriasis, or drug hypersensitivity. Distinguishing erythrodermic mycosis fungoides from Sezary syndrome requires careful assessment of blood involvement and clonal evidence. International staging criteria guide prognosis and treatment selection.
Treatment
Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.
Management is individualized and directed by a multidisciplinary team spanning dermatology, hematology-oncology, and supportive care.
Foundational and supportive care: Aggressive skin care with emollients, antipruritic agents, and infection prevention measures are central given the compromised skin barrier. Systemic antihistamines and topical preparations mitigate pruritus. Nutritional support and surveillance for secondary infections are maintained throughout.
Targeted therapy: Mogamulizumab (POTELIGEO) is an approved treatment for Sezary syndrome. This CCR4-directed monoclonal antibody targets a receptor expressed on the malignant T-cells and has demonstrated clinical benefit. Eligibility depends on individual factors discussed with the care team.
Investigational approaches: Additional therapies are under clinical investigation, including agents with orphan drug designation for cutaneous T-cell lymphoma. Eligibility depends on individual factors discussed with the care team.
Based on GeneReviews surveillance recommendations, HPO phenotype frequency and severity annotations, and published prevalence estimates from Orphanet and OMIM.
Sezary syndrome carries a serious prognosis given its leukemic presentation and systemic involvement. The course tends to be aggressive, with many individuals experiencing progression despite treatment. Infectious complications from impaired skin barrier and immunosuppression are a primary cause of morbidity and mortality. Prognosis is shaped by extent of blood involvement, treatment response, and performance status. Access to specialized cutaneous lymphoma centers is associated with improved outcomes.
Research Landscape
Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.
Numerous active clinical trials are evaluating novel therapies for Sezary syndrome, including targeted immunotherapies, combination regimens, and agents with novel mechanisms of action. Biomarker research seeks predictors of treatment response and progression. Translational studies are exploring the molecular basis of malignant T-cell transformation to identify new therapeutic targets. Individuals may wish to discuss trial eligibility with their care team.
The program has received Fast Track designation from the FDA, PRIME designation from the EMA for Sézary syndrome, Orphan Drug designation in both the U.S. and EU for CTCL, and Breakthrough Therapy Designation from the FDA for relapsed or refractory Sézary syndrome. The program is advancing toward a pivotal Phase 3 TELLOMAK-3 study, an open-label, multicenter, randomized trial in patients with Sézary syndrome and mycosis fungoides who have failed at least one prior systemic therapy. The study includes a confirmatory cohort in Sézary syndrome intended to support a potential accelerated approval and upon study completion a full approval for Sézary syndrome, and a registrational cohort in mycosis fungoides intended to support full approval, with progression-free survival (PFS) as the primary endpoint. ... Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Leveraging its expertise in antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics. Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL. “This agreement is an important step in strengthening our portfolio and reflects our strategy of partnering with leading innovators to bring differentiated therapies to patients with rare diseases.
The program has received Fast Track designation from the U.S. Food and Drug Administration (FDA), PRIME designation from the European Medicines Agency (EMA) for Sézary syndrome, Orphan Drug designation in both the U.S. and EU for CTCL, and Breakthrough Therapy Designation from the FDA for ... The program has received Fast Track designation from the U.S. Food and Drug Administration (FDA), PRIME designation from the European Medicines Agency (EMA) for Sézary syndrome, Orphan Drug designation in both the U.S. and EU for CTCL, and Breakthrough Therapy Designation from the FDA for relapsed or refractory Sézary syndrome. AFT Pharmaceuticals Secures FDA Tentative Approval for Scomara in Facial Angiofibromas, US Launch Delayed Until 2029 ... Emmaus Life Sciences Grants Exclusive North American Rights for Sickle Cell Drug Endari to NeoImmuneTech ... OSE Immunotherapeutics Expands Lusvertikimab Program with New Autoimmune Indications in 2026-2028 Strategic Plan ... Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi ... ... Swedish Orphan Biovitrum AB: Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma The collaboration, announced on August 10, 2026, will enable the initiation of the TELLOMAK-3 confirmatory Phase 3 study, a pivotal step in the drug's regulatory pathway. "This agreement is an important step in strengthening our portfolio and reflects our strategy of partnering with leading innovators to bring differentiated therapies to patients with rare diseases," said Guido Oelkers, President and CEO of Sobi. Under the terms of the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in CTCL. The study is designed as an open-label, multicenter, randomized trial enrolling patients with Sézary syndrome and mycosis fungoides — the most common CTCL subtype — who have failed at least one prior systemic therapy.
An update from Swedish Orphan Biovitrum AB ( ($SE:SOBI) ) is now available. Sobi has struck a strategic partnership with Innate Pharma to license lacutamab, a first... Sobi has struck a strategic partnership with Innate Pharma to license lacutamab, a first-in-class anti-KIR3DL2 antibody, for cutaneous T-cell lymphoma, securing exclusive global commercial rights upon potential accelerated approval. The deal underpins the launch of the pivotal TELLOMAK-3 Phase 3 trial in Sézary syndrome and mycosis fungoides, bolstering Sobi’s oncology footprint in rare hematologic cancers. Swedish Orphan Biovitrum AB, known as Sobi, is a global biopharmaceutical company focused on rare diseases, with a portfolio of breakthrough therapies targeting underserved patient populations. The agreement includes up to USD 580 million in upfront and milestone payments plus royalties, strengthening Sobi’s rare oncology pipeline and financing Innate’s Phase 3 TELLOMAK-3 trial.
The program has received Fast Track designation from the FDA, PRIME designation from the EMA for Sézary syndrome, Orphan Drug designation in both the · U.S. and EU for CTCL, and Breakthrough Therapy Designation from the FDA for relapsed or refractory Sézary syndrome. Sobi deal remains subject to closing conditions, including antitrust clearance; its $75M upfront payment at closing is expected to extend cash runway through Q3 2027. Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability. ... A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. The program is advancing toward a pivotal Phase 3 TELLOMAK-3 study, an open-label, multicenter, randomized trial in patients with Sézary syndrome and mycosis fungoides who have failed at least one prior systemic therapy. The study includes a confirmatory cohort in Sézary syndrome intended to support a potential accelerated approval and upon study completion a full approval for Sézary syndrome, and a registrational cohort in mycosis fungoides intended to support full approval, with progression-free survival (PFS) as the primary endpoint. ... Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.
